58,380 research outputs found
Working at Home in the Ancient Near East: New Insights and Avenues of Research
No full textPreface to the volume Working at Home in the Ancient Near Eas
A long-term study on the setting reaction of glass ionomer cements by Al-27 MAS-NMR spectroscopy
No full text25/09/12 MEB. Author version attached, OK to publis
Detailed results of Multilabel Prototype Generation for Data Reduction in k-Nearest Neighour classification
No full textDetailed experimental results of both the proposed and existing multilabel Prototype Generation methods for Data Reduction in k-Nearest Neighbour classification:1. General Multilabel PG comparative- General comparison of the proposed methods against the existing proposals in the literature.- Individual results provided for each corpus.- Corresponds to Section 5.1 in the manuscript.2. Noise robustness- Study of the noise robustness capabilities of the proposed strategies as well as the existing methods.- Individual results provided for each corpus.- Corresponds to Section 5.2 in the manuscript.3. Imbalanced data- Assessment considering imbalanced data metrics.- Individual results provided for each corpus.- Corresponds to Section 5.3 in the manuscript.4. Execution time bechmarking- Benchmarking comparative, in terms of execution time, of the assessed methods.- Individual results provided for each iteration considered.- Corresponds to Section 5.4 in the manuscript
Detailed results of Multilabel Prototype Generation for Data Reduction in k-Nearest Neighour classification
No full textDetailed experimental results of both the proposed and existing multilabel Prototype Generation methods for Data Reduction in k-Nearest Neighbour classification:1. General Multilabel PG comparative- General comparison of the proposed methods against the existing proposals in the literature.- Individual results provided for each corpus.- Corresponds to Section 5.1 in the manuscript.2. Noise robustness- Study of the noise robustness capabilities of the proposed strategies as well as the existing methods.- Individual results provided for each corpus.- Corresponds to Section 5.2 in the manuscript.3. Imbalanced data- Assessment considering imbalanced data metrics.- Individual results provided for each corpus.- Corresponds to Section 5.3 in the manuscript.4. Execution time bechmarking- Benchmarking comparative, in terms of execution time, of the assessed methods.- Individual results provided for each iteration considered.- Corresponds to Section 5.4 in the manuscript
Letter from Mas Sakai to Sakai family, October 12, 1942
No full textTwo letters from Mas Sakai to the Sakai Family, sent from Tanforan Assembly Center, informing the family that he will be leaving for Utah the following day. The letter is laced with sarcasm as Sakai describes living conditions at Tanforan ("it wouldn't be right if I called it a concentration camp would it? After all we get the freedom of the track, don't we?"), and incarcerees' expectations of life at Topaz ("we all look to Utah with a song in our hearts (a funeral march) for there are our golden opportunities. Wonderful, trackless, sand to plant in, and cool refreshing salt water to drink. We especially look forward to the toilets (no seats)").Personal correspondence, organizational records, government documents, publications, and other papers created or collected by Joseph R. Goodman documenting the forced removal and incarceration of Japanese Americans during World War II, as well as organized resistance to incarceration. Included in the collection are records of the Japanese Young Men's Christian Association and the Japanese American Citizens' League in San Francisco, including papers of the Japanese YMCA's executive secretary Lincoln Kanai; Sakai family papers; Goodman's correspondence to and from Japanese American incarcerees, organizations opposing forced removal and incarceration of Japanese Americans, the War Relocation Authority, and others; publications, photographs, and ephemera from the Topaz Relocation Center, where Goodman taught high school; War Relocation Authority records and publications; and newspaper clippings, pamphlets, and reports about forced removal and incarceration created by various government, religious, and civic organizations, in California and nationwide
Huesca / J. Mas g[rabó]
No full text1 Mapa, col. Probablement dins: Atlas geográfico ibero-americano de B. Chias, o algun dels atles derivats Datació aproximada.[1:350 000 aprox]32 x 42 cm en full de 39 x 52 c
Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions
No full textThe impairment of arterial baroreceptor and vasodilator functions are two major contributors to the hypertensive action of cyclosporine (CSA). In this study, in vivo and in vitro pharmacological studies were performed to investigate whether these effects of CSA are differentially modulated by endothelin and thromboxane signaling. The treatment of rats with CSA (25 mg-kg-day i.p.) for 7 consecutive days caused significant increases in blood pressure (BP), attenuated reflex heart rate (HR) responses to vasopressor (phenylephrine, PE) and vasodepressor (sodium nitroprusside, SNP) agents, and reduced cumulative vasorelaxant responses elicited by acetylcholine (Ach, 1×10-9-1×10-5 M) in PE-precontracted isolated aortas. These effects of CSA were blunted after concurrent i.p. administration of atrasentan (selective ETA blocker, 10 mg-kg-day), but not terutroban (thromboxane receptor blocker, 10 mg-kg-day). Moreover, atrasentan reversed the reductions in aortic protein expression of eNOS caused by CSA whereas terutroban was without effect. We also report that the favorable effect of atrasentan on CSA-evoked impairment in aortic Ach responsiveness disappeared in rats treated simultaneously with L-NAME (NOS inhibitor, 10 mg-kg-day) but not BQ 788 (ETB receptor blocker, 0.1 mg-kg-day) or indomethacin (cycloxygenase inhibitor, 5 mg-kg-day). Together, the data implicate endothelin ETA receptors in baroreflex and vascular derangements which predispose to the hypertensive effect of CSA. Moreover, the facilitation of NOS, but not ETB receptors or cycloxygenase-derived prostanoids, signaling is pivotal for advantageous effect of atrasentan on the aortic CSA-Ach interaction. © 2014 Elsevier B.V.Bartholomeusz B, 1996, HYPERTENSION, V27, P1341; Bischoff A, 1998, J PHARMACOL EXP THER, V286, P704; BOKEMEYER D, 1994, CLIN SCI, V87, P383; Bourque SL, 2011, AM J PHYSIOL-REG I, V300, pR1288, DOI 10.1152-ajpregu.00397.2010; Bryan RM, 2005, ANESTHESIOLOGY, V102, P1261, DOI 10.1097-00000542-200506000-00028; Cai GJ, 2005, ATHEROSCLEROSIS, V183, P41, DOI 10.1016-j.athersclerosis.2005.03.037; Câmara Paula Rs, 2012, World J Gastrointest Pathophysiol, V3, P85, DOI 10.4291-wjgp.v3.i4.85; Cauduro RL, 2005, CLIN TRANSPLANT, V19, P470, DOI 10.1111-j.1399-0012.2005.00357.x; CHAPLEAU MW, 1992, AM J PHYSIOL, V263, pR103; David OJ, 2001, THER DRUG MONIT, V23, P100, DOI 10.1097-00007691-200104000-00003; De Ferrari GM, 2007, J AM COLL CARDIOL, V50, P2285, DOI 10.1016-j.jacc.2007.08.043; De La Cruz JP, 2012, DIABETES-METAB RES, V28, P132, DOI 10.1002-dmrr.1283; Dhaun N, 2008, HYPERTENSION, V52, P452, DOI 10.1161-HYPERTENSIONAHA.108.117366; DiCarlo SE, 2001, ANN NY ACAD SCI, V940, P324; Ebrahim Z, 2001, AM J PHYSIOL-HEART C, V281, pH1458; El-Gowilly SM, 2008, CLIN EXP PHARMACOL P, V35, P1164, DOI 10.1111-j.1440-1681.2008.04983.x; El-Mas MM, 2003, CLIN EXP HYPERTENS, V25, P381; El-Mas MM, 2008, J PHARMACOL EXP THER, V324, P368, DOI 10.1124-jpet.107.127498; ElMas MM, 1997, EUR J PHARMACOL, V322, P201, DOI 10.1016-S0014-2999(97)00010-1; El-Mas MM, 2011, EUR J PHARMACOL, V650, P317, DOI 10.1016-j.ejphar.2010.10.032; El-Mas MM, 2003, EUR J PHARMACOL, V468, P217, DOI 10.1016-S0014-2999(03)01720-5; El-Mas MM, 2012, NEUROPHARMACOLOGY, V62, P1890, DOI 10.1016-j.neuropharm.2011.12.017; El-Mas MM, 1999, J CARDIOVASC PHARM, V34, P589, DOI 10.1097-00005344-199910000-00017; El-Mas MM, 2004, EUR J PHARMACOL, V487, P149, DOI 10.1016-j.ejphar.2004.01.025; ElMas MM, 1997, EUR J PHARMACOL, V337, P235, DOI 10.1016-S0014-2999(97)01283-1; El-Mas MM, 2002, J PHARMACOL EXP THER, V301, P346, DOI 10.1124-jpet.301.1.346; Fardin NM, 2012, OBESITY, V20, P1591, DOI 10.1038-oby.2012.4; Fischer D, 2005, EUR HEART J, V26, P65, DOI 10.1093-eurheartj-ehi001; Gerhardt U, 1999, INT J CARDIOL, V68, P203, DOI 10.1016-S0167-5273(98)00368-4; GLEN JB, 1973, BRIT VET J, V129, P471; GOLDSTEIN DS, 1983, CIRCULATION, V68, P234; GORDON FJ, 1983, AM J PHYSIOL, V245, pH210; Hardy G, 2000, J CARDIOVASC PHARM, V36, P693, DOI 10.1097-00005344-200012000-00002; Hoorn EJ, 2012, J NEPHROL, V25, P269, DOI 10.5301-jn.5000174; Jarvis MF, 2000, EUR J PHARMACOL, V388, P29, DOI 10.1016-S0014-2999(99)00865-1; LYSON T, 1994, HYPERTENSION, V23, P667; Mathieu P, 1996, ANN CHIR, V50, P682; MUNCH PA, 1994, CIRC RES, V74, P422; Nakahata N, 2008, PHARMACOL THERAPEUT, V118, P18, DOI 10.1016-j.pharmthera.2008.01.001; Nishiyama A, 2003, HYPERTENSION, V42, P754, DOI 10.1161-01.HYP.0000085195.38870.44; Oriji GK, 2003, PROSTAG LEUKOTR ESS, V68, P233, DOI 10.1016-S0952-3278(02)00276-4; PERICO N, 1986, AM J PHYSIOL, V251, pF581; PHILLIPS PA, 1994, CLIN EXP PHARMACOL P, V21, P223, DOI 10.1111-j.1440-1681.1994.tb02501.x; Ramzy D, 2006, CIRCULATION, V114, pI214, DOI 10.1161-CIRCULATIONAHA.105.000471; Salgado MCO, 2006, AM J PHYSIOL-HEART C, V290, pH1059, DOI 10.1152-ajpheart.00219.2005; Sebekova K, 2007, DIABETES, V56, P968, DOI 10.2337-db06-1136; Sellers MM, 2008, AM J PHYSIOL-HEART C, V294, pH1978, DOI 10.1152-ajpheart.01318.2007; Singh M, 2010, CARDIOL CLIN, V28, P545, DOI 10.1016-j.ccl.2010.07.001; Souza HCD, 2008, CLIN EXP PHARMACOL P, V35, P751, DOI [10.1111-j.1440-1681.2008.04866.x, 10.1111-j.1440-1681.2007.04866.x]; Spieker LE, 2000, J AM COLL CARDIOL, V36, P213, DOI 10.1016-S0735-1097(00)00674-4; Sykora M, 2009, STROKE, V40, pE678, DOI 10.1161-STROKEAHA.109.565838; Thorin E, 2010, PFLUG ARCH EUR J PHY, V459, P951, DOI 10.1007-s00424-009-0763-y; TRESHAM JJ, 1990, TRANSPLANTATION, V49, P144, DOI 10.1097-00007890-199001000-0003212
- …
